Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

Mario Hose Mario Hose, news.financial
0 Comments| July 15, 2020

{{labelSign}}  Favorites
{{errorMessage}}

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Legalization in the USA is expected

Medical cannabis is already legalized in 33 states in the USA and thus about 221 million people, about 67% of the total US population, have access to the natural substance. Fifty years ago, only about 12% of US citizens were in favor of legalizing marijuana, but since then the popularity has grown to 66%.

In addition, the racism debate in the USA also plays a role in the legalization issue, because around 80% of arrests involving marijuana affect people with dark skin. For this reason, experts assume that a legalization of cannabis at the federal level will take place within the next two years - detached from the outcome of the elections in November 2020.

Recovery of the cannabis industry expected

In the tailwind of a legalization in the USA and the increasing use of cannabis in medicine, EXMceuticals (CSE: EXM) and XPhyto (CSE: XPHY) will also grow. Both companies are active in the cannabis sector and thus part of the expanding eco-system of products, therapies and suppliers. The quality and individuality will become increasingly important.

For this reason, it can be worthwhile to focus more on smaller companies than on the big players who try to cover the whole value chain with a lot of money. Usually too much complexity leads to inefficiency. Therefore, focused niche players can have an advantage.

Vaccine can slow down Covid-19

BioNTech (NASDAQ: BNTX) also focuses on individuality, as the company is working on the development of individualized options for the treatment of cancer. In addition, the biotech company is currently working with Pfizer on the development of a vaccine against Covid-19 in order to be able to limit the spread of the pandemic. In view of the fact that new hotspots of spread are constantly emerging worldwide, the global demand for a vaccine is correspondingly high.

CONFLICT OF INTEREST & RISK NOTE

We would like to point out that Apaton Finance GmbH, the owner of news.financial, as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions

in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our ´Conflict of Interest & Risk Disclosure´.


{{labelSign}}  Favorites
{{errorMessage}}

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to be able to post a comment.

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company